hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06352528 id: CA127-1070 briefTitle: A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2025-07-24 date: 2025-07-24 date: 2024-04-08 date: 2024-04-08 name: Bristol-Myers Squibb class: INDUSTRY briefSummary: The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function. conditions: Hepatic Impairment conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Repotrectinib measure: Maximum observed plasma concentration (Cmax) measure: Time of maximum observed plasma concentration (Tmax) measure: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) measure: Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) measure: Number of participants with Adverse Events (AEs) measure: Number of participants with Severe Adverse Events (SAEs) measure: Number of participants with physical examination abnormalities measure: Number of participants with vital sign abnormalities measure: Number of participants with electrocardiogram (ECG) abnormalities measure: Number of participants with clinical safety laboratory test abnormalities sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Local Institution - 0003 city: Miami Lakes state: Florida zip: 33014 country: United States name: Site 0003 role: CONTACT lat: 25.90871 lon: -80.30866 facility: Local Institution - 0001 city: Orlando state: Florida zip: 32809 country: United States name: Site 0001 role: CONTACT lat: 28.53834 lon: -81.37924 facility: Local Institution - 0002 city: San Antonio state: Texas zip: 78215 country: United States name: Site 0002 role: CONTACT lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06352515 id: T cells in Ulcerative colitis briefTitle: T Lymphocyte Subsets in Ulcerative Colitis overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-01 date: 2027-06-01 date: 2024-04-08 date: 2024-04-29 name: Assiut University class: OTHER briefSummary: 1. Study the distribution of peripheral blood T lymphocyte subsets among ulcerative colitis patients.
3. Assess the value of circulating IgG anti-Integrin αvβ6 in UC. conditions: Ulcerative Colitis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 80 type: ESTIMATED name: Flow cytometry measure: Study the distribution of T-cell subsets among ulcerative colitis patients. measure: Correlation of T-cell subtypes to therapeutic response sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352502 id: 202112-28 briefTitle: An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis overallStatus: RECRUITING date: 2022-01-28 date: 2024-09-30 date: 2024-09-30 date: 2024-04-08 date: 2024-04-08 name: Tang-Du Hospital class: OTHER briefSummary: EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M mutation positive NSCLC. This study aims to investigate the efficacy and safety of furmonertinib in the treatment of EGFR-sensitive mutation positive NSCLC patients with brain metastasis. conditions: EGF-R Positive Non-Small Cell Lung Cancer conditions: CNS Metastases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Furmonertinib measure: Intracranial Objective response rate measure: Intracranial Disease Control Rate measure: Intracranial progression-free survival measure: Progression-free survival measure: Overall Survival measure: Safety/Adverse event sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tangdu Hopspital status: RECRUITING city: Xi'an state: Shanxi zip: 710038 country: China name: Haichuan Su, PhD role: CONTACT phone: 18629190366 email: such@fmmu.edu.cn name: Jie Min, PhD role: CONTACT phone: 13709202616 email: minjie1504@163.com name: Haichuan Su, PhD role: PRINCIPAL_INVESTIGATOR name: Jie Min, PhD role: SUB_INVESTIGATOR lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06352489 id: Posterior component separation briefTitle: Evaluation of Posterior Component Separation Technique in the Management of Complex Ventral Hernia. overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05 date: 2026-06 date: 2024-04-08 date: 2024-04-08 name: Assiut University class: OTHER briefSummary: * Assess short term outcome of posterior component separation technique(PCS) including the regain of the physiological function of the abdominal wall.
* Detect most common post operative complications related to AWR techniques in a 6 months duration after operation. conditions: Ventral Hernia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Posterior component separation technique. measure: Hernia recurrence measure: post operative short term complications sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352476 id: 10881-669 briefTitle: The Effect of Sleep Hygiene Given to Epilepsy Patients on Seizure Frequency and Sleep Quality overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-01 date: 2024-12-01 date: 2024-12-01 date: 2024-04-08 date: 2024-04-08 name: Marmara University class: OTHER briefSummary: Epilepsy is a disease that can be seen in everyone, including neurological, chronic, elderly and children. An estimated 50 million people in the world have epilepsy, patients have a history of two or more seizures, the exact cause is unknown, it negatively affects home, work and school life, and it directs individuals from their independent roles to semi-dependent and fully dependent roles (Smith \& Wagner \& Jonathan, 2015). "Neuronal networks hypersynchronization" develops epileptic seizures, can cause insomnia, and sleep quality may decrease with drug treatment (Sünter and Ağan, 2019). NREM sleep causes seizures through the "ictal and interactive effect" of sleep (Alp and Altındağ, 2014). Insomnia increases seizure discharges, neurological and systemic complications may develop, and serious morbidity and mortality may occur (Özer, 2005). Epilepsy patients frequently experience daytime sleepiness and nighttime insomnia (Gümüşyayla and Vural, 2017). Complementary medical approaches are also recommended along with drug treatment. Sleep hygiene training is recommended for sleep health in epilepsy as in chronic diseases. With good sleep health, symptoms can be eliminated and sequelae can be prevented by reducing epileptic discharges (Gammino at all., 2016). Quality sleep is essential for physiological and psychological health, and sleep disorders can be corrected with sleep hygiene training (Günaş, 2018). Randomized studies including sleep hygiene training are needed to prevent seizure recurrences, prevent or treat comorbid psychological diseases, and improve life activities of epilepsy patients (Lee at all., 2015). One-third of people's lives are spent in sleep, regular and adequate sleep protects physiological and psychological health, sleep hygiene training contributes to the recovery of sleep disorders and accompanying psychological comorbid diseases, sleep hygiene training is cost-free and easy to implement, where daily activities and behaviors are regulated, appropriate environmental conditions are provided. By regulating the circadian rhythm, melatonin is released during sleep at night and sleep disorders are prevented by preventing excessive cortisol release (http://www.psikiyatri.net/uyku-hijyeni / Access date: 28 May 2022; Alp and Altındağ, 2014; Güneş, 2018). . No research has been found on sleep hygiene training to relieve sleep deprivation, which is common in epilepsy patients. With good sleep hygiene, sleep and quality of life can be improved and epileptic seizures can be prevented or reduced.
Purpose of the research; To determine the effect of sleep hygiene training given to epilepsy patients on seizure frequency and sleep quality. Non-drug clinical research is an experimentally planned research with a pre-test post-test control group trial model. conditions: Epilepsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The research is an experimental study with a pre-test and post-test control group trial model. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: The participant will not know whether he or she is in the experimental or control group. whoMasked: PARTICIPANT count: 160 type: ESTIMATED name: Sleep Hygiene Training measure: Pittsburgh Sleep Quality Index measure: Pittsburgh Sleep Quality Index measure: epileptic seizure diary sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marmara University city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06352463 id: 406.XS.03.068 briefTitle: Intervention Social Anxiety: Combining Parent-child Treatment acronym: ISA overallStatus: RECRUITING date: 2024-04-15 date: 2025-07-01 date: 2025-07-01 date: 2024-04-08 date: 2024-04-08 name: Leiden University class: OTHER name: Leids Universitair Behandel en Expertise Centrum (LUBEC) name: GGZ Delfland name: Netherlands Organisation for Scientific Research briefSummary: The aim of this pilot project is to investigate a treatment program for children with social anxiety, in which children and their parents, parallel to each other, follow separate evidence-based interventions. The added value of this pilot project is that the investigators are examining how both programs interact when offered simultaneously. conditions: Social Anxiety Disorder of Childhood studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 9 type: ESTIMATED name: Denken + Doen = Durven name: Supportive Parenting for Anxious Childhood Emotions measure: Change in severity of social anxiety in children measure: Change in anxiety-related symptoms and family accommodation sex: ALL minimumAge: 8 Years maximumAge: 16 Years stdAges: CHILD facility: GGZ Delfland status: NOT_YET_RECRUITING city: Delft state: South-Holland zip: 2600GA country: Netherlands name: Anika Bexkens role: CONTACT email: a.bexkens@fsw.leidenuniv.nl lat: 52.00667 lon: 4.35556 facility: Leiden University status: RECRUITING city: Leiden state: South-Holland zip: 2333AK country: Netherlands lat: 52.15833 lon: 4.49306 facility: LUBEC status: RECRUITING city: Leiden state: South-Holland zip: 2333ZB country: Netherlands name: Anika Bexkens role: CONTACT email: a.bexkens@fsw.leidenuniv.nl lat: 52.15833 lon: 4.49306 hasResults: False
nctId: NCT06352450 id: DPT/Batch-Fall19/558 briefTitle: Comparison of Active Isolated Stretching Versus Myofascial Release of Knee Joint in Office Workers overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-15 date: 2024-05-20 date: 2024-06-28 date: 2024-04-08 date: 2024-04-08 name: Superior University class: OTHER briefSummary: "Office workers often spend long hours sitting, which can lead to stiffness and reduced mobility. By studying these two techniques AIS and MFR, we can determine which one is more effective in helping office workers to improve their flexibility and range of motion in the knee joint because their sedentary work environment often leads to musculoskeletal issues, including limited knee joint mobility.
Understanding the benefits and effectiveness of these techniques will contribute to evidence-based practices in occupational health and help office workers maintain optimal joint health" conditions: Stiffness; Spine conditions: Mobility Limitation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: Active isolated stretching (AIS) name: Myofascial release (MFR) measure: Numaric Pain Scale sex: ALL minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT facility: Al-Zahra Medical complex Johar town, Laser spine center Model town, Laser spine center Johar town. city: Lahore country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06352437 id: 1507-0001 id: 2023-508767-79-00 type: REGISTRY domain: CTIS id: U1111-1302-5933 type: REGISTRY domain: WHO International Clinical Trials Registry Platform (ICTRP) briefTitle: A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-07-14 date: 2025-07-14 date: 2024-04-08 date: 2024-04-08 name: Boehringer Ingelheim class: INDUSTRY briefSummary: This study is open to healthy people and people with overweight or obesity. It has 2 parts. Part A is open to healthy men between 18 and 55 years of age. Part B is open to people between 18 and 65 years of age with overweight or obesity who are otherwise healthy.
Participants in Part A are in the study up to 10 weeks. During this time, they visit the study site 8 times. Participants in Part B are in the study for about 6 months. They visit the study regularly. At some of the visits, participants in both parts stay at the study site for up to 5 nights. During the study, the doctors collect information on any health problems of the participants. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 124 type: ESTIMATED name: BI 3034701 name: Placebo matching BI 3034701 measure: Part A and Part B: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator measure: Part A: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) following a single dose of BI 3034701 measure: Part A: Maximum measured concentration of the analyte in plasma (Cmax) following a single dose of BI 3034701 measure: Part B: Area under the concentration-time curve in plasma over the time interval from 0 to 168 hours (AUC0-168) following multiple doses of BI 3034701 measure: Part B: Maximum measured concentration of the analyte in plasma (Cmax) following multiple doses of BI 3034701 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352424 id: 1458-0006 id: 2023-506233-30-01 type: REGISTRY domain: CTIS (EU) id: U1111-1293-4672 type: REGISTRY domain: WHO Registry briefTitle: A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-12-09 date: 2024-12-09 date: 2024-04-08 date: 2024-04-08 name: Boehringer Ingelheim class: INDUSTRY briefSummary: The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity. conditions: Obesity studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 24 type: ESTIMATED name: BI 456906 name: BI 1820237 name: Placebo for BI 1820237 name: Placebo for BI 456906 measure: Blood Oxygen Level Dependent (BOLD) signal changes following treatment with single dose of BI 1820237 alone, BI 456906 alone, and combination of BI 1820237 + BI 456906 versus placebo sex: ALL minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06352411 id: 1404-0009 id: 2023-508557-13-00 type: REGISTRY domain: CTIS id: U1111-1298-3135 type: REGISTRY domain: WHO registry briefTitle: A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2024-11-26 date: 2024-11-26 date: 2024-04-08 date: 2024-04-08 name: Boehringer Ingelheim class: INDUSTRY briefSummary: This study is open to adults aged between 18 and 80 years of age with a body mass index (BMI) of 20 to 40 kg/m2. People with or without kidney problems can take part in the study.
Participants are in the study for about 2 months. They stay for 5 days and 4 nights at the study site and visit their doctors about 7 times. During these visits, the doctors collect information about participants' health. To assess the study endpoints, the doctors regularly take blood samples from the participants. The participants also answer questions about their well-being. The doctors regularly check participants' health and take note of any unwanted effects. conditions: Healthy conditions: Renal Impairment studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: BI 456906 measure: Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) measure: Maximum measured concentration of BI 456906 in plasma (Cmax) measure: Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) measure: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352398 id: BBTuysuz briefTitle: Comparison of Analgesic Efficacy in Video-Assisted Thoracoscopic Surgery Patients overallStatus: COMPLETED date: 2023-12-20 date: 2024-02-01 date: 2024-04-01 date: 2024-04-08 date: 2024-04-08 name: Burcu Bozdogan Tuysuz class: OTHER briefSummary: The 52 patients included in the study were divided into two groups as ESPB (n=26) and SPSIPB (n=26). Before the operation, 0.25% bupivacaine 30 ml was administered to both groups. After admission to the operating room, all patients underwent standard anaesthesia procedures. Morphine 0.05 mg/kg i.v. and parol 1 g i.v. were administered 30 min before the end of the operation. Post operatively the patient was followed up with controlled analgesia. Demographic data, ASA scores, body mass indexes, peri-operative haemodynamic values, remifentanil consumption and duration of surgery were recorded. Post-operative first 24 hours NRS scores, morphine consumption, number of nausea and vomiting episodes were recorded. conditions: Video-Assisted Thoracoscopic Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 52 type: ACTUAL name: erector spina plan block name: Serratus posterior superior intercostal plan block (SPSIPB) name: 0.25% bupivacaine measure: morphine consumption first 24 hours measure: NRS pain score sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istanbul Medenıyet Unıversıty city: Istanbul state: Kadıkoy zip: 34734 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06352385 id: SH9H-2024-TK16-1.0 briefTitle: Epidemiological Investigation of Malocclusion in China overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-12 date: 2026-12 date: 2024-04-08 date: 2024-04-08 name: Shanghai Jiao Tong University School of Medicine class: OTHER briefSummary: Malocclusion is a kind of craniomaxillofacial complex deformity caused by heredity, environment, bad habits, trauma, inflammation, tumor and aging. Notably, the last comprehensive national prevalence data on malocclusion in China, which encompassed a significant sample size, dates back over two decades. Given the evolving nature of these epidemiological metrics, such as prevalence rates, it is imperative to update our understanding. Consequently, there is an urgent need for China to undertake a unified, standardized epidemiological survey of malocclusion with a substantial sample size to ensure accurate and timely data collection. conditions: Epidemiological Investigation conditions: Malocclusion studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 19847 type: ESTIMATED measure: The Prevalence rate of malocclusion measure: Dental Aesthetic Index of each age group measure: Index of Orthodontic Treatment Need of each age group measure: dietary habit measure: oral hygiene habits measure: Bad oral habit sex: ALL minimumAge: 4 Years maximumAge: 20 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06352372 id: tPBM Study briefTitle: Safety and Efficacy of tPBM for Epileptiform Activity in Autism acronym: tPBM overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-06 date: 2024-04-08 date: 2024-04-08 name: Richard Frye class: OTHER briefSummary: For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. This will occur, twice a week, for 10 weeks. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills. Cognilum may impact the clinical practice of treating autism. At the beginning, at five weeks, and at the end of study, the clinician will complete the CARS-2, SRS, CGI, and a caregiver interview; additionally, questionnaires will be administered to caregivers during one of the 1-hour weekly treatment sessions. conditions: Autism Spectrum Disorder conditions: EEG With Periodic Abnormalities conditions: Epilepsy conditions: Neurodevelopmental Disorders conditions: Neurological Disorder studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a prospective, open label study comparing 15 individuals with active seizures and 15 individuals with EEG abnormalities before and after treatment with, near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) measure: Childhood Autism Rating Scores (CARS) measure: EEG Delta Power measure: Seizure frequency and severity measure: Social Responsiveness Scale (SRS) measure: Clinical Global Impression Scale (CGI) measure: NIH Toolbox sex: ALL minimumAge: 4 Years maximumAge: 12 Years stdAges: CHILD facility: Rossignol Medical Center city: Phoenix state: Arizona zip: 85050 country: United States name: Richard E Frye, M.D., PhD role: CONTACT phone: 321-259-7111 email: drfrye@rossignolmedicalcenter.com name: Richard E Frye, M.D., PhD role: PRINCIPAL_INVESTIGATOR lat: 33.44838 lon: -112.07404 hasResults: False